Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed metastatic or locally advanced adenocarcinoma of the pancreas~  * Patients with clinical 'high probability' of pancreatic cancer and biopsy suggestive but not diagnostic of pancreatic cancer may be eligible based on review by the principal investigator~* Measurable or evaluable disease~* No clinical evidence of active venous thromboembolism~PATIENT CHARACTERISTICS:~* Karnofsky performance status (PS) 60-100% OR WHO PS 0-2~* Life expectancy \> 12 weeks~* Absolute neutrophil count \> 2,000/mm³~* WBC \> 3,000/mm³~* Platelet count \> 100,000/mm³~* Creatinine clearance \> 50 mL/min~* INR ≤ 1.5 times upper limit of normal (ULN)~* Bilirubin \< 1.5 times ULN (stent allowed)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No cerebrovascular accident within the past 6 months~* No obvious contraindication to anticoagulation, including the following:~  * Bleeding diathesis~ * Active peptic ulcer~ * Ulcerating cancer into duodenum~* No history of other advanced malignancy~* No gross hematuria~* No melaena or gross evidence of gastrointestinal bleeding (other than piles)~* No requirement for a central line~* No other significant medial or psychiatric illness that, in the opinion of the investigator, would preclude study participation~PRIOR CONCURRENT THERAPY:~* No prior gemcitabine hydrochloride-containing treatment~* No other concurrent cytotoxic chemotherapy, immunotherapy, hormonal therapy (excluding contraceptives and replacement steroids), or experimental medications~* No other concurrent specific anticancer therapy as a result of disease progression~* No concurrent caval filter device~* No other concurrent anticoagulants for venous thromboembolism or other reasons (e.g., atrial fibrillation)~* No concurrent acetylsalicylic acid (\> 75 mg) as an antiplatelet drug for a preexisting cardiovascular condition~* No concurrent clopidogrel bisulfate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).